Earnings
Insight Molecular Diagnostics Faces January FDA Deadline — Missing It Would Restart Its Test Review
Management is preparing a clinical-kit launch while expanding the evidence for its kidney-transplant test and proposing a stock offering.
Insight Molecular Diagnostics (IMDX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management is preparing a clinical-kit launch while expanding the evidence for its kidney-transplant test and proposing a stock offering.
SEC Filings
Lower submission costs helped curb spending, but FDA authorization remains the gate to meaningful clinical-test kit sales.